Fast Track Group FTRK 深 滬
等待開盤 11-26 09:30:00 美东时间
0.4073
+0.025
+6.62%
華盛通- 最 高0.4204
- 今 開0.3653
- 成交量 38.55万股
- 最 低 0.3653
- 昨 收 0.382
- 總市值 888.42万
- 52周最高 9.69
- 市盈率 靜 --
- 換手率 1.77%
- 52周最低 0.2916
- 委 比 -99.80%
- 總股本 2181.25万
- 歷史最高 9.69
- 量 比 0.19
- 振 幅 14.42%
- 歷史最低 0.2916
- 每 手 1
- 風險率 1.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline
Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, raising concerns for next-generation tau-targeting drug programs.
今天 01:22
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
BiomX is addressing FDA follow-up requests regarding the nebulizer device used in its Phase 2b trial for BX004, targeting *P. aeruginosa* in cystic fibrosis patients. An independent DMC completed a safety review, recommending continued study with revised dosing. The trial protocol is being updated, and top-line results are now expected in Q2 2026. Enrollment in the U.S. will resume once FDA requests are resolved.
11-25 21:40
Bayer Says New Daily Pill Cuts Risk of Repeat Stroke Without Extra Bleeding Risk
Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy and safety
11-24 16:04
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics Ltd. announced that its co-founder and CEO, Dr. Adi Mor, will present at Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City. Dr. Mor will provide a corporate overview and hold one-on-one meetings with attendees. Chemomab is a biotech company developing innovative therapeutics for fibro-inflammatory diseases, particularly focusing on nebokitug, a first-in-class monoclonal antibody targeting CCL...
11-24 13:00
Iterum Therapeutics Provides Business Update
<p>Iterum Therapeutics has announced updates on its business, including the stocking of ORLYNVAH™ at McKesson and the FDA clearance of its sulopenem susceptibility disc. ORLYNVAH™ is now available through McKesson's specialty distribution channel, allowing physicians to procure the product directly. The FDA-cleared disc, manufactured by Liofilchem®, is intended for use in microbiology laboratories for susceptibility testing to determine Enterobac...
11-24 13:00
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that its management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET. A live webcast will be available on the Company’s website, and a replay will follow. Seres Therapeutics focuses on developing live biotherapeutics to improve outcomes for medically vulnerable popula...
11-24 12:00
Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
Scilex Holding Company has announced the exercise of existing warrants, raising approximately $20.3 million. The warrants, issued in April 2024 and December 2024, cover a total of 904,396 shares. In exchange, the Company issued new warrants for 1,356,594 shares with a $29.00 exercise price, valid for five years. Proceeds will support working capital and general corporate activities. The new warrants were issued under private placement.
11-24 11:00
10 Communication Services Stocks Moving In Thursday's Pre-Market Session
Gainers iHeartMedia (NASDAQ:IHRT) stock increased by 9.9% to $4.32 during Thur...
11-20 20:05
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd announced positive updates on its nebokitug Phase 3 trial design for primary sclerosing cholangitis (PSC), receiving support from both the FDA and EMA for a single registration trial using a clinical event composite endpoint. Data from the Phase 2 SPRING trial's open-label extension (OLE) showed favorable safety and consistent improvements in key biomarkers, further reinforcing nebokitug's disease-modifying potential. Th...
11-20 13:00
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
Can-Fite BioPharma Ltd. announced receiving a patent allowance for CF602 in Brazil, targeting erectile dysfunction in diabetic patients and non-responders to existing ED drugs. CF602, an A3 adenosine receptor modulator, shows potential to address unmet needs in the $3.2 billion ED market. It offers restored muscle collagen and endothelial function in diabetic models. This expansion complements existing U.S. and European patents, highlighting its ...
11-20 12:00
